Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

As 2025 comes to a close, people turn to the highlights of what made the year special…or at least bearable. There were plenty of viral trends and memes that took over the internet this year, though ...

Java 26, due in March with structured concurrency, lazy constants, AOT object caching, and primitive types in patterns, instanceof, and switch, has entered a second rampdown phase for bug fixes. Java ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

The internet is vast, and it feels pretty much infinite. And you know what that means? A never-ending supply of its favorite animals: cats. No matter where you look, there’s a feline for every ...